Lagadinou ED, Sach A, Callahan K, Rossi RM, Neering SJ, Minhajuddin M, Ashton JM, Pei S, Grose V, ODwyer KM, Liesveld JL, Brookes PS, Becker MW, Jordan CT
Targeting TNFR2 as a novel therapeutic strategy for Alzheimers Disease
Most patients on a supervised injectable MOTS-c protocol at Perfect B begin noticing changes in energy and body composition at the 3 to 4 week mark, with more meaningful metabolic improvements building over a full 8 to 12 week cycle
Fetal hemoglobin can also be increased with hydroxycarbamide (Hydrea), an anti-cancer drug (Wang 2011)
Pro-cholinergic pharmacological agents also provide symptomatic improvement in FGIDs (213, 214)
The drugs (GABA, DSIP, DSIP-CBBBP, and CBBBP) were administered via i.p